查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1981739

多體學市場：按產品類型、技術、應用和最終用戶分類－2026-2032年全球市場預測

Multiomics Market by Product Type, Technology, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年多體學市場價值 26.2 億美元，預計到 2026 年將成長至 29.3 億美元，複合年成長率為 12.50%，到 2032 年將達到 59.8 億美元。

主要市場統計數據
基準年 2025 26.2億美元
預計年份：2026年 29.3億美元
預測年份 2032 59.8億美元
複合年成長率 (%) 12.50%

我們將多組體學定位為一個綜合領域，它結合了技術進步、資料管治和轉化重點，並將其策略性地引入以指導投資指南。

多組體學正在重塑機構建構和解答生物學問題的方式，本文將該領域置於技術、資料科學和轉化應用目標的交匯點。過去十年，研究人員已摒棄了孤立的檢測方法，轉而採用整合基因組學、轉錄組學、蛋白質組學、代謝體學、脂類組學學和表觀基因數據的策略。這揭示了在單體學方法中常常被忽略的機制。因此，在實驗設計中，樣本完整性、統一的元元資料和分析可重複性如今同等重要，以確保跨組體學方法的可比性。

重大變革正在重塑多組體學的應用，這是由技術融合、法規演變以及對檢驗的轉化工作流程的需求所驅動的。

多組體學領域正經歷著一場變革性的轉型，其驅動力來自技術融合、不斷變化的臨床需求以及新興資料科學能力。定序能力和準確性的提升、先進的質譜平台以及自動化的樣本製備流程正在降低技術門檻，並擴大可行的研究設計範圍。同時，機器學習和網路生物學領域的演算法創新正在開闢新的解讀層面，使研究人員能夠從複雜的多維資料集中推導出機制性假設。

本分析探討了關稅壓力對供應鏈的影響如何推動體學學價值鏈的在地化、供應商多元化和彈性籌資策略。

2025年美國關稅環境對多組體學生態系統內的供應鏈韌性、籌資策略和成本結構提出了實際挑戰。對實驗室設備、試劑或進口組件徵收關稅可能會增加總體成本，迫使製造商和買家評估替代供應商、實現關鍵生產過程本地化或重新談判供應商合約。為此，許多機構正在重新評估其平台投資的總體擁有成本 (TCO)，並優先考慮那些供應鏈透明且製造地分散的供應商。

全面的細分洞察揭示了技術選擇、體學方法、產品類型、應用和最終用戶需求如何決定採用路徑和價值創造。

關鍵的細分洞察揭示了技術選擇、科學研究重點和終端用戶需求之間的交集，從而塑造了技術應用路徑和價值提案。基於技術，市場涵蓋質譜、微陣列、qPCR 和定序，其中定序又細分為次世代定序和桑格定序。這些技術的組合決定了處理能力、靈敏度以及研究人員可應用的下游分析類型。基於體學，該領域延伸至表觀基因、基因組學、脂類組學、代謝體學、蛋白質組學和轉錄組學。每個體學層面都具有其獨特的生物學背景，並帶來與樣品製備、動態範圍和數據整合相關的固有分析挑戰。

可操作的區域見解解釋了美洲、歐洲、中東和非洲以及亞太地區的趨勢如何影響多組體學的技術採用、監管和夥伴關係策略。

區域趨勢對多組體學領域的技術應用、監管協調和夥伴關係策略產生了深遠影響。在美洲，研究活動、創業投資資金以及強大的生物技術叢集網路正在推動先進定序和質譜平台的快速應用。然而，複雜的報銷機制和法規結構要求制定有針對性的檢驗策略。同時，該地區的產學研合作以及合約研究組織（CRO）正在促進轉化研究流程的構建，從而加速概念驗證（PoC）研究和早期臨床應用。

主要企業洞察強調了平台整合、檢驗能力和服務差異化如何決定多體學領域中每個參與者的競爭優勢。

多組體學領域的競爭格局歸根結底在於能否提供可靠、檢驗的端到端解決方案，這些方案需結合高性能儀器、可重複使用的耗材和可擴展的分析能力。主要企業透過投資平台互通性、在臨床或農業環境中驗證其效用，以及透過夥伴關係將其價值提案擴展到下游應用，從而脫穎而出。策略併購和夥伴關係活動不斷將專業能力（例如小眾樣品製備技術和先進資訊學）與更廣泛的平台提供者相結合，旨在提供全面的服務。

為行業領導者提供可操作的建議，以增強平台互通性、供應鏈韌性、監管合規性和服務主導的商業化策略。

行業領導者可以透過優先考慮韌性和以客戶為中心，同時使策略行動與技術和監管現實相符，從而加速價值創造。首先，投資可互通平台和開放資料標準可以減少整合摩擦，並增強解決方案對擁有異質基礎設施的終端用戶的吸引力。其次，擴大本地生產和建立區域夥伴關係可以降低關稅和供應鏈風險，同時縮短關鍵耗材和試劑的交付時間。

為了確保分析的有效性和相關性，我們採用了嚴謹的混合方法調查方法，將對專家的直接訪談與第二手資料。

本調查方法透過整合一手和二手研究，確保分析的嚴謹性、可重複性和有效性。一手研究包括對領域專家、實驗室主任和服務供應商進行結構化訪談，以了解實際操作、檢驗流程和採購因素。這些定性資訊與技術文獻、同行評審研究和供應商文件進行交叉比對，以檢驗有關平台功能、檢測局限性和分析工作流程的說法。

決定性的整合凸顯了對檢驗的工作流程、可互通的平台以及強大的商業化策略的必要性，以實現多體學的影響。

總之，多組體學代表著生命科學領域的一個策略轉折點，它整合了分子譜分析、先進儀器和複雜分析方法，從而能夠提供更深入的生物學見解並產生轉化應用的影響。該領域的成熟需要技術創新，同時輔以穩健的資料管治、標準化的工作流程和具有商業性可行性的服務模式，以降低應用門檻。政策變化和貿易趨勢凸顯了供應鏈韌性和區域靈活性的重要性，因此，在地化和夥伴關係策略對於長期業務永續營運至關重要。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 多組體學市場：依產品類型分類

  • 消耗品
  • 裝置
  • 軟體和服務
    • 服務
      • 數據分析
      • 樣品製備
    • 軟體

第9章：多組體學市場：依技術分類

  • 質譜分析
  • 微陣列
  • qPCR
  • 定序
    • 次世代定序
    • 桑格定序

第10章：多組體學市場：依應用分類

  • 農業和食品檢驗
  • 生物標記發現
  • 臨床診斷
  • 藥物發現與開發
  • 個人化醫療

第11章：多組體學市場：依最終用戶分類

  • 學術研究機構
  • 合約研究機構
  • 醫院和診斷檢測實驗室
  • 製藥和生物技術公司

第12章 多組體學市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：多組體學市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 多組體學市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國多組體學市場

第16章：中國多體學市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • Bruker Corporation
  • Danaher Corporation
  • Illumina, Inc.
  • PerkinElmer, Inc.
  • QIAGEN NV
  • Roche Holding AG
  • Thermo Fisher Scientific Inc.
  • Waters Corporation
Product Code: MRR-CF699CF41428

The Multiomics Market was valued at USD 2.62 billion in 2025 and is projected to grow to USD 2.93 billion in 2026, with a CAGR of 12.50%, reaching USD 5.98 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.62 billion
Estimated Year [2026] USD 2.93 billion
Forecast Year [2032] USD 5.98 billion
CAGR (%) 12.50%

A strategic introduction framing multiomics as an integrative discipline that fuses technological advances, data governance, and translational priorities to guide investment

Multiomics is reshaping how organizations ask and answer biological questions, and this introduction situates the field at the intersection of technology, data science, and translational ambition. Over the past decade, practitioners have moved beyond siloed assays to integrated strategies that layer genomics, transcriptomics, proteomics, metabolomics, lipidomics, and epigenomics data to reveal mechanistic insights that single-omic approaches often miss. Consequently, experimental design now places equal emphasis on sample integrity, harmonized metadata, and analytical reproducibility to support cross-omic comparability.

As multiomics applications expand from discovery biology into clinical diagnostics, drug development, and personalized medicine, stakeholders must reconcile differing regulatory expectations, data governance frameworks, and validation requirements. This evolution elevates the importance of standardized protocols and interoperable data formats, while simultaneously driving demand for analytics platforms that translate heterogenous datasets into clinically meaningful signatures. Moreover, advances in sequencing chemistry, mass spectrometry sensitivity, and computational tools have reduced technical barriers, encouraging cross-disciplinary collaboration among wet-lab scientists, bioinformaticians, and clinicians.

Taken together, these dynamics position multiomics as both a scientific enabler and a strategic lever. Institutions that align organizational processes, invest in reproducible workflows, and foster data-driven cultures are best placed to capture the translational value of integrated molecular profiling. The remainder of this executive summary unpacks the transformative shifts, policy impacts, segmentation insights, and regional considerations that will shape adoption and competitive differentiation.

Key transformative shifts reshaping multiomics adoption driven by convergent technologies, regulatory evolution, and demand for validated translational workflows

The landscape of multiomics is undergoing transformative shifts driven by converging technological advances, evolving clinical priorities, and emergent data science capabilities. Improvements in sequencing throughput and accuracy, enhanced mass spectrometry platforms, and automated sample preparation workflows are lowering technical friction and expanding the range of feasible study designs. Simultaneously, algorithmic innovations in machine learning and network biology are unlocking new interpretive layers, enabling researchers to extract mechanistic hypotheses from complex, multi-dimensional datasets.

At the same time, regulatory and ethical considerations are reshaping how organizations approach data stewardship. Greater emphasis on provenance, auditability, and cross-institutional data sharing is accelerating investments in secure platforms and federated analysis models that preserve patient privacy while enabling large-scale integrative studies. Clinical demand for actionable biomarkers, coupled with heightened expectations for analytical validation and clinical utility, is pushing developers to prioritize reproducibility and transparent performance metrics.

Operationally, there is a clear move toward end-to-end solutions that combine consumables, instruments, and services into validated workflows. This trend supports faster translational timelines and reduces the integration burden for end users. Taken together, these shifts create an environment where strategic partnerships, platform interoperability, and demonstrable clinical impact determine long-term success.

Analyzing how tariff-driven supply chain pressures compel localization, supplier diversification, and resilient procurement strategies across the multiomics value chain

The 2025 tariff environment in the United States has introduced tangible considerations for supply chain resilience, procurement strategy, and cost structure within the multiomics ecosystem. Tariffs on laboratory instruments, reagents, or imported components can increase landed costs, prompting manufacturers and buyers to evaluate sourcing alternatives, localize critical production steps, or renegotiate supplier agreements. In response, many organizations are reassessing total cost of ownership for platform investments and prioritizing vendors that demonstrate transparent supply chains and diversified manufacturing footprints.

These policy shifts also amplify the strategic value of regional partnerships and distributed manufacturing models. Firms that can scale localized assembly, consumable production, or reagent fill-and-finish capacities gain a competitive advantage under tariff pressures. Meanwhile, service providers with flexible, regionally distributed laboratories can mitigate exposure by reallocating sample processing to facilities with preferential trade terms or lower import duties.

From a procurement perspective, research institutions and commercial labs are increasingly adopting multi-year contracts, hedging strategies, and inventory management practices to absorb short-term price volatility. At the same time, the need for clear visibility into upstream component sourcing has elevated supplier audits and contractual clauses that address tariff-related liabilities. Ultimately, the policy environment is pushing the sector toward more resilient, transparent, and geographically diversified supply chains that preserve scientific continuity while controlling operational risk.

Comprehensive segmentation insights revealing how technology choices, omic modalities, product types, applications, and end-user needs determine adoption pathways and value creation

Key segmentation insights reveal where technological choices, scientific priorities, and end-user needs intersect to shape adoption pathways and value propositions. Based on Technology, the market encompasses Mass Spectrometry, Microarrays, qPCR, and Sequencing, with Sequencing further segmented into Next Generation Sequencing and Sanger Sequencing; this technological palette determines throughput, sensitivity, and the nature of downstream analytics that researchers can apply. Based on Omics, the field spans Epigenomics, Genomics, Lipidomics, Metabolomics, Proteomics, and Transcriptomics; each omic layer contributes distinct biological context and poses unique analytical challenges related to sample prep, dynamic range, and data integration.

Based on Product Type, offerings include Consumables, Instruments, and Software and Services, with Software and Services further differentiated into Services and Software, and Services subdivided into Data Analysis and Sample Preparation; such product taxonomy underscores the growing importance of bundled solutions that combine hardware with analytical and preparatory services. Based on Application, primary use cases encompass Agriculture and Food Testing, Biomarker Discovery, Clinical Diagnostics, Drug Discovery and Development, and Personalized Medicine; these applications drive differing requirements for regulatory compliance, throughput, and interpretive frameworks. Based on End User, the ecosystem serves Academic and Research Institutes, Contract Research Organizations, Hospitals and Diagnostic Laboratories, and Pharmaceutical and Biotechnology Companies; each end-user segment prioritizes distinct value drivers, from exploratory flexibility to validated, clinically compliant workflows.

Interpreting these segmentations together highlights where investments will matter most: platforms that enable high-quality sample processing, interoperable data pipelines that support multi-omic integration, and services that reduce technical barriers for non-specialist end users. In short, success hinges on aligning technological capabilities with application-specific needs and end-user operational realities.

Actionable regional insights describing how Americas, Europe Middle East & Africa, and Asia-Pacific dynamics influence adoption, regulation, and partnership strategies in multiomics

Regional dynamics exert a powerful influence on technology deployment, regulatory alignment, and partnership strategies across the multiomics landscape. In the Americas, research intensity, venture funding, and a robust network of biotech clusters drive rapid adoption of advanced sequencing and mass spectrometry platforms, while a complex patchwork of reimbursement and regulatory frameworks requires targeted validation strategies. Meanwhile, academic-industry collaborations and contract research organizations in the region foster translational pipelines that accelerate proof-of-concept studies and early clinical adoption.

Across Europe, Middle East & Africa, regulatory harmonization efforts, strong public research infrastructures, and growing commercial investment support methodical integration of multiomics into healthcare and agricultural applications. Stakeholders in these markets often prioritize interoperability, data protection, and harmonized performance standards, creating demand for validated workflows and compliant analytics. In Asia-Pacific, rapid infrastructure build-out, manufacturing scale, and government-led science initiatives are expanding local production capacities and driving aggressive adoption of sequencing technologies and automated sample handling systems. The region's diverse regulatory environments and large patient populations also create opportunities for large-scale cohort studies and localized biomarker discovery.

Collectively, these regional characteristics underscore the need for geographically nuanced strategies. Organizations must tailor commercialization, regulatory, and partnership approaches to regional priorities, balancing global platform standardization with local operational flexibility.

Key company insights highlighting how platform integration, validation capabilities, and service differentiation determine competitive advantage across multiomics players

Competitive dynamics in multiomics center on the ability to deliver reliable, validated end-to-end solutions that combine high-performance instruments, reproducible consumables, and scalable analytics. Key companies distinguish themselves through investments in platform interoperability, demonstrated clinical or agricultural utility, and partnerships that extend their value proposition into downstream applications. Strategic M&A and partnership activity continues to align specialized capabilities-such as niche sample preparation chemistry or advanced informatics-with broader platform providers seeking comprehensive offerings.

Market differentiation also arises from service excellence; organizations that provide robust validation support, regulatory documentation, and training resources secure deeper customer relationships. Similarly, firms that offer modular software with open APIs facilitate integration into existing laboratory information management systems and analysis pipelines, lowering barriers for enterprise adoption. Investors and strategic partners increasingly prize companies that demonstrate end-user-focused commercialization strategies, geographic manufacturing resilience, and transparent data governance practices. Ultimately, market leaders combine technical credibility with commercial agility, enabling them to scale adoption across academic, clinical, and industrial customers.

Actionable recommendations for industry leaders to enhance platform interoperability, supply chain resilience, regulatory support, and service-led commercialization strategies

Industry leaders can accelerate value capture by aligning strategic actions with technological and regulatory realities while prioritizing resilience and customer-centricity. First, investing in interoperable platforms and open data standards reduces integration friction and increases the appeal of solutions across end users with heterogeneous infrastructure. Next, expanding localized manufacturing or establishing regional partnerships mitigates tariff and supply chain risks, while offering faster turnaround times for critical consumables and reagents.

Additionally, integrating comprehensive validation packages and regulatory support into product offerings lowers adoption barriers in clinical and diagnostic contexts. Leaders should also develop tiered service models that include sample preparation, data analysis, and clinical interpretation to address the needs of both high-throughput research centers and diagnostic laboratories. To cultivate long-term trust, companies must implement transparent data governance frameworks and robust provenance tracking to satisfy institutional and regulatory auditors. Finally, strengthening cross-disciplinary talent pipelines-combining wet-lab expertise, computational biology, and regulatory affairs-ensures organizations can translate multiomic data into actionable biological and clinical insights. These recommendations form a pragmatic blueprint for organizations seeking to scale responsibly and sustainably.

A rigorous mixed-methods research methodology combining expert primary interviews with systematic secondary evidence synthesis to ensure analytic validity and relevance

The research methodology blends primary and secondary evidence to ensure analytical rigor, reproducibility, and relevance. Primary research included structured interviews with domain experts, laboratory directors, and service providers to capture operational realities, validation practices, and procurement drivers. These qualitative inputs were triangulated with technical literature, peer-reviewed studies, and vendor documentation to verify claims about platform capabilities, assay limitations, and analytical workflows.

Secondary research encompassed a systematic review of scientific publications, regulatory guidance documents, and white papers that illuminate technological trends and application-specific requirements. Data collection prioritized sources that detail assay performance characteristics, sample handling best practices, and interoperability standards. Findings were synthesized using thematic analysis and cross-validation steps to surface consistent patterns and areas of divergence. Throughout the process, attention to provenance, methodological transparency, and source credibility underpinned analytical choices, ensuring that conclusions rest on verifiable evidence and reflect current industry practices.

A conclusive synthesis emphasizing the need for validated workflows, interoperable platforms, and resilient commercialization strategies to realize multiomics impact

In conclusion, multiomics represents a strategic inflection point in life sciences where integrated molecular profiling, advanced instrumentation, and sophisticated analytics converge to enable deeper biological insight and translational impact. The field's maturation depends on aligning technological innovation with robust data governance, standardized workflows, and commercially viable service models that lower barriers to adoption. Policy shifts and trade dynamics have highlighted the importance of supply chain resilience and regional agility, making localization and partnership strategies central to long-term operational continuity.

Looking ahead, organizations that prioritize platform interoperability, end-to-end validation, and customer-focused service offerings will be best positioned to translate multiomic data into clinical and commercial outcomes. Cross-sector collaboration among instrument vendors, software developers, service providers, and end users will accelerate the development of validated workflows and reproducible evidence, thereby expanding the range of practical applications. Ultimately, the pathway to impact lies in coupling scientific rigor with pragmatic commercialization and governance frameworks that foster trust, scalability, and measurable benefit.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Multiomics Market, by Product Type

  • 8.1. Consumables
  • 8.2. Instruments
  • 8.3. Software and Services
    • 8.3.1. Services
      • 8.3.1.1. Data Analysis
      • 8.3.1.2. Sample Preparation
    • 8.3.2. Software

9. Multiomics Market, by Technology

  • 9.1. Mass Spectrometry
  • 9.2. Microarrays
  • 9.3. qPCR
  • 9.4. Sequencing
    • 9.4.1. Next Generation Sequencing
    • 9.4.2. Sanger Sequencing

10. Multiomics Market, by Application

  • 10.1. Agriculture and Food Testing
  • 10.2. Biomarker Discovery
  • 10.3. Clinical Diagnostics
  • 10.4. Drug Discovery and Development
  • 10.5. Personalized Medicine

11. Multiomics Market, by End User

  • 11.1. Academic and Research Institutes
  • 11.2. Contract Research Organizations
  • 11.3. Hospitals and Diagnostic Laboratories
  • 11.4. Pharmaceutical and Biotechnology Companies

12. Multiomics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Multiomics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Multiomics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Multiomics Market

16. China Multiomics Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Agilent Technologies, Inc.
  • 17.6. Bio-Rad Laboratories, Inc.
  • 17.7. Bruker Corporation
  • 17.8. Danaher Corporation
  • 17.9. Illumina, Inc.
  • 17.10. PerkinElmer, Inc.
  • 17.11. QIAGEN N.V.
  • 17.12. Roche Holding AG
  • 17.13. Thermo Fisher Scientific Inc.
  • 17.14. Waters Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL MULTIOMICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MULTIOMICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL MULTIOMICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL MULTIOMICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL MULTIOMICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MULTIOMICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL MULTIOMICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MULTIOMICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL MULTIOMICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MULTIOMICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES MULTIOMICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA MULTIOMICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL MULTIOMICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL MULTIOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MULTIOMICS MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL MULTIOMICS MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL MULTIOMICS MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MULTIOMICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MULTIOMICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MULTIOMICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MULTIOMICS MARKET SIZE, BY SOFTWARE AND SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MULTIOMICS MARKET SIZE, BY SOFTWARE AND SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MULTIOMICS MARKET SIZE, BY SOFTWARE AND SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MULTIOMICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MULTIOMICS MARKET SIZE, BY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MULTIOMICS MARKET SIZE, BY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MULTIOMICS MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MULTIOMICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MULTIOMICS MARKET SIZE, BY DATA ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MULTIOMICS MARKET SIZE, BY DATA ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MULTIOMICS MARKET SIZE, BY DATA ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MULTIOMICS MARKET SIZE, BY SAMPLE PREPARATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MULTIOMICS MARKET SIZE, BY SAMPLE PREPARATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MULTIOMICS MARKET SIZE, BY SAMPLE PREPARATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MULTIOMICS MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MULTIOMICS MARKET SIZE, BY SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MULTIOMICS MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MULTIOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MULTIOMICS MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MULTIOMICS MARKET SIZE, BY MASS SPECTROMETRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MULTIOMICS MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MULTIOMICS MARKET SIZE, BY MICROARRAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MULTIOMICS MARKET SIZE, BY MICROARRAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MULTIOMICS MARKET SIZE, BY MICROARRAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MULTIOMICS MARKET SIZE, BY QPCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MULTIOMICS MARKET SIZE, BY QPCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MULTIOMICS MARKET SIZE, BY QPCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MULTIOMICS MARKET SIZE, BY SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MULTIOMICS MARKET SIZE, BY SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MULTIOMICS MARKET SIZE, BY SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MULTIOMICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MULTIOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL MULTIOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MULTIOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL MULTIOMICS MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MULTIOMICS MARKET SIZE, BY SANGER SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MULTIOMICS MARKET SIZE, BY SANGER SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL MULTIOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL MULTIOMICS MARKET SIZE, BY AGRICULTURE AND FOOD TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL MULTIOMICS MARKET SIZE, BY AGRICULTURE AND FOOD TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL MULTIOMICS MARKET SIZE, BY AGRICULTURE AND FOOD TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL MULTIOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL MULTIOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL MULTIOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL MULTIOMICS MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL MULTIOMICS MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL MULTIOMICS MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL MULTIOMICS MARKET SIZE, BY DRUG DISCOVERY AND DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL MULTIOMICS MARKET SIZE, BY DRUG DISCOVERY AND DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL MULTIOMICS MARKET SIZE, BY DRUG DISCOVERY AND DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL MULTIOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL MULTIOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL MULTIOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL MULTIOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL MULTIOMICS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL MULTIOMICS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL MULTIOMICS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL MULTIOMICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL MULTIOMICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL MULTIOMICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL MULTIOMICS MARKET SIZE, BY HOSPITALS AND DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL MULTIOMICS MARKET SIZE, BY HOSPITALS AND DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL MULTIOMICS MARKET SIZE, BY HOSPITALS AND DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL MULTIOMICS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL MULTIOMICS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL MULTIOMICS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL MULTIOMICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS MULTIOMICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS MULTIOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS MULTIOMICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS MULTIOMICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS MULTIOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS MULTIOMICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS MULTIOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS MULTIOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA MULTIOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA MULTIOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA MULTIOMICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA MULTIOMICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA MULTIOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA MULTIOMICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA MULTIOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA MULTIOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA MULTIOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA MULTIOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA MULTIOMICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA MULTIOMICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA MULTIOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA MULTIOMICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA MULTIOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA MULTIOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA MULTIOMICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA MULTIOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA MULTIOMICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA MULTIOMICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA MULTIOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA MULTIOMICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA MULTIOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA MULTIOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE MULTIOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE MULTIOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE MULTIOMICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE MULTIOMICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE MULTIOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE MULTIOMICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE MULTIOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE MULTIOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST MULTIOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST MULTIOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST MULTIOMICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST MULTIOMICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST MULTIOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST MULTIOMICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST MULTIOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST MULTIOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA MULTIOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA MULTIOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA MULTIOMICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA MULTIOMICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA MULTIOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA MULTIOMICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA MULTIOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA MULTIOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC MULTIOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC MULTIOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC MULTIOMICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC MULTIOMICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC MULTIOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC MULTIOMICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC MULTIOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC MULTIOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL MULTIOMICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN MULTIOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN MULTIOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN MULTIOMICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN MULTIOMICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN MULTIOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN MULTIOMICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN MULTIOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN MULTIOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. GCC MULTIOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GCC MULTIOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. GCC MULTIOMICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 152. GCC MULTIOMICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 153. GCC MULTIOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 154. GCC MULTIOMICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 155. GCC MULTIOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 156. GCC MULTIOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION MULTIOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION MULTIOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION MULTIOMICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION MULTIOMICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION MULTIOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION MULTIOMICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION MULTIOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION MULTIOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS MULTIOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. BRICS MULTIOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. BRICS MULTIOMICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS MULTIOMICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS MULTIOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 170. BRICS MULTIOMICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS MULTIOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS MULTIOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. G7 MULTIOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. G7 MULTIOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. G7 MULTIOMICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 176. G7 MULTIOMICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 177. G7 MULTIOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 178. G7 MULTIOMICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 179. G7 MULTIOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 180. G7 MULTIOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. NATO MULTIOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. NATO MULTIOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. NATO MULTIOMICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 184. NATO MULTIOMICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 185. NATO MULTIOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 186. NATO MULTIOMICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 187. NATO MULTIOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 188. NATO MULTIOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL MULTIOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. UNITED STATES MULTIOMICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 191. UNITED STATES MULTIOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. UNITED STATES MULTIOMICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED STATES MULTIOMICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED STATES MULTIOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 195. UNITED STATES MULTIOMICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED STATES MULTIOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED STATES MULTIOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. CHINA MULTIOMICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 199. CHINA MULTIOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. CHINA MULTIOMICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 201. CHINA MULTIOMICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 202. CHINA MULTIOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 203. CHINA MULTIOMICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 204. CHINA MULTIOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 205. CHINA MULTIOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)